EUVIMEDSkopri EUVIMED
EUVIMED · CrossrefJournal

International Journal of Lung Cancer

ISSN 3117-504X · Elsevier BV

Latest articles

  1. Frequency and safety of pegfilgrastim use in patients with lung cancer treated with combination therapy of cytotoxic chemotherapy and immune checkpoint inhibitors: A CS-lung-003-registry-based prospective observational study

    Tomoki Tamura, Kazuya Nishii, Yukari Tsubata, Naoki Watanabe, Masahiro Kodani, Takeshi Masuda, Masaaki Inoue, Masahiro Yamasaki, Nobuaki Ochi, Tetsuya Kubota, Hirohisa Ichikawa, Nobuhisa Ishikawa, Shingo Harita, Nobukazu Fujimoto, Ichiro Takata, Soichi Kitaguchi, Tatsuya Nishi, Naoki Nakamura, Katsuyuki Hotta, Katsuyuki Kiura

    Published: 2026-12DOI: 10.1016/j.ijlcan.2026.100065

  2. The changing landscape of stage IV lung squamous cell carcinoma: Long-term trends with immune checkpoint inhibitors and contemporary regimens

    Aastha Dhakal, Emily C. Zabor, Naveen Rehman, Bridget Adcock, Muaz Alsabbagh Alchirazi, Moath Albliwi, Ali Mushtaq, Hadil Zureigat, Monica Lee, Ahmed Nabil Mohamed Hassan, Heya Batah, Preeyal Patel, Meera Patel, Sara Haddad, Yang Wang, Michael Menefee, Khaled Aref Hassan, Marc A. Shapiro, James Stevenson, Alex A. Adjei, Lukas Delasos, Moaath Khader Mustafa Ali

    Published: 2026-12DOI: 10.1016/j.ijlcan.2026.100070

  3. Adjuvant alectinib versus platinum-based chemotherapy in patients from Asia with completely resected ALK-positive non-small cell lung cancer (NSCLC): an exploratory subgroup analysis of ALINA including pharmacokinetics and safety in Japanese patients

    Makoto Nishio, Benjamin J. Solomon, Fabrice Barlesi, Rafal Dziadziuszko, Yi-Long Wu, Cheng-Ta Yang, Dae Ho Lee, Hidehito Horinouchi, Jong-Seok Lee, Krittiya Korphaisarn, Qun Wang, Shun Lu, Wenzhao Zhong, Weimin Mao, Astrid Scalori, Dhruvitkumar S. Sutaria, Lilian Bu, Miki Nomura, Patricia Petric, Takuya Yoshimoto, Tingting Xu, Jin Seok Ahn

    Published: 2026-08DOI: 10.1016/j.ijlcan.2026.100062

Volumes

2026 · 75

Għarfien li jaqbel max-xogħol tiegħek.

Minn bidu b’xejn u riċerka personali tal-letteratura sal-Research Suite sħiħa.

Ara t-tariffi →

Il-full texts kollha tal-pubblikaturi huma inklużi?

Le. Ir-referenzi biblijografiċi, l-astratti u t-testi sħaħ huma kontenuti differenti. Jekk test sħiħ huwiex disponibbli jiddependi mis-sors, Open Access u l-liċenzji eżistenti tiegħek. Pjan ta’ EUVIMED ma jissostitwix drittijiet addizzjonali tal-pubblikaturi.